Latest Newsletters

• Fall/ Winter 2011
• Spring 2011
• Winter 2010

Upcoming Events

Latest News

• May 16: Worldwide Recognition of hae day :-) Unites and Empowers the Global Hereditary Angioedema Community
• May 16: Dyax Corp. Reaffirms Commitment to Supporting Patients with Hereditary Angioedema on Inaugural HAE Day
• May 15: Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
• May 12: Dyax Corp. Launches Hereditary Angioedema (HAE) Attack Tracker™, a Free iPhone Application for HAE Patients
• May 4: CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

ViroPharma And Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20)

Dec 6, 2011 | www.viropharma.com

EXTON, Pa., Dec. 6, 2011 /PRNewswire/ — ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) today announced positive top line data from ViroPharma’s open-label, multiple dose Phase 2 clinical trial designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme’s Enhanze™ technology, a proprietary drug delivery platform using Halozyme’s recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE), a rare, debilitating and potentially fatal genetic disease.

In this study, the addition of rHuPH20 led to higher maximum levels and greater systemic exposure of functional and antigenic C1 inhibitor (C1 INH) for both Cinryze doses evaluated (1000 and 2000 units) as compared to subcutaneous administration of Cinryze alone. In addition, administration of Cinryze with rHuPH20 resulted in mean functional C1 INH levels that are clinically relevant and potentially associated with protection against HAE attacks. The most commonly reported adverse events are mild local injection site reactions such as erythema and pain.